05 Aug 2026
- Gross margin impacted by geopolitical cost pressures; full-year margin guidance maintained at 21-22%
- India business growth guidance 12-15% with volume-led growth and new product launches
- Key priorities: US respiratory launches in H2 FY27, oncology launches Aumolertinib, Trastuzumab Rezetecan, envafolimab